Chemotherapy, Adjuvant
10
1
3
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
20.0%
2 terminated out of 10 trials
50.0%
-36.5% vs benchmark
30%
3 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)
Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC
POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Adjuvant FEC Versus EP in Breast Cancer (MIG5)
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer